Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20

Trial Profile

Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2013

At a glance

  • Drugs Rituximab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Zenyaku Kogyo
  • Most Recent Events

    • 08 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top